Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.

ABSTRACT:

Background

Treatment targets for ulcerative colitis are evolving towards achievement of endoscopic improvement and remission in addition to symptom resolution. It remains to be accurately quantified what proportion of patients with symptom resolution have residual endoscopic activity that might warrant treatment modification.

Aim

To quantify the prevalence of endoscopic improvement and remission amongst ulcerative colitis patients with various permutations of patient-reported outcomes.

Methods

Individual participant data from active intervention and placebo arms of clinical trials of infliximab, golimumab, vedolizumab and tofacitinib were pooled to estimate the prevalence of endoscopic improvement (Mayo endoscopic sub-score [MES] 0 or 1) and remission (MES 0) scores w

SUBMITTER: Dulai PS 

PROVIDER: S-EPMC6989392 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature